- US-listed companies
- Protagonist Therapeutics, Inc
- Income statement
Protagonist Therapeutics, Inc【PTGX】Income statement
Market cap
$5B
P/E ratio
| 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | - | - | 31 | - | - | 27 | 27 | 60 | 434 |
| Revenue growth (%) | - | - | - | - | - | - | |||
| Research & development | 26 | 46 | 59 | 65 | 75 | 126 | 126 | 120 | 138 |
| Operating margin (%) | - | - | - | - | |||||
| Operating income | -33 | -38 | -42 | -81 | -65 | -126 | -131 | -94 | 253 |
| Operating expenses | 33 | 58 | 73 | 81 | 93 | 153 | 158 | 154 | 182 |
| Income before tax | - | - | -40 | -78 | -65 | -126 | -127 | - | 279 |
| Pretax margin (%) | - | - | -128.4 | - | - | -458.9 | -479.3 | - | 64.3 |
| Provision for income taxes | - | - | 1 | -1 | 1 | - | - | - | 4 |
| Effective tax rate (%) | - | - | - | - | - | ||||
| Net income | -37 | -37 | -39 | -77 | -66 | -126 | -127 | -79 | 275 |
| Net income margin (%) | - | - | - | - | |||||
| Earnings per share | - | - | - | - | - | - | -2.6 | -1.39 | 4.47 |
| Diluted EPS | - | - | - | - | - | - | -2.6 | -1.39 | 4.23 |
| EBITDA | |||||||||
| EBITDA margin (%) | - | - | - | - |